Immuno-oncology technology最新文献_第9页

64P Artificial intelligence (AI) tools established for the optimization of immunotherapy of cancer 建立64P人工智能（AI）工具，优化癌症免疫治疗

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101147

A.A. Tarhini, P. Dave, I. El Naqa

引用次数: 0

7P MTAP-deletion and correlation with tumor microenvironment in resected stage IIIpN2-NSCLC: A LungART trial substudy 在切除的iii期ipn2 - nsclc中，7P mtap缺失及其与肿瘤微环境的相关性：LungART试验亚研究

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101092

D. Diaz-Jimenez , M.R. Ghigna , V.M. Albarran Artahona , A. Lopez Gutierrez , J. Adam , M. Aldea , J-P. Dales , G. Granier , N. Cozic , F. Barlesi , D. Planchard , A. Levy , C. Le Pechoux , B. Besse , J. Remon Masip

引用次数: 0

Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells T细胞活化抑制因子和程序性死亡-1的配体与受体相互作用抑制T细胞的抗癌活性

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-11-13 DOI: 10.1016/j.iotech.2025.101533

M. Abooali , X. Lei , I.M. Yasinska , S. Schlichtner , R. Hussain , G. Siligardi , T.-M. Gianga , S.M. Berger , D. Cholewa , B.F. Gibbs , E. Fasler-Kan , V.V. Sumbayev

{"title":"Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells","authors":"M. Abooali , X. Lei , I.M. Yasinska , S. Schlichtner , R. Hussain , G. Siligardi , T.-M. Gianga , S.M. Berger , D. Cholewa , B.F. Gibbs , E. Fasler-Kan , V.V. Sumbayev","doi":"10.1016/j.iotech.2025.101533","DOIUrl":"10.1016/j.iotech.2025.101533","url":null,"abstract":"<div><h3>Background</h3><div>V-domain immunoglobulin-containing suppressor of T cell activation (VISTA) is a unique multifunctional immune checkpoint protein, which can display both receptor and ligand properties. It plays a crucial role in the cancer immune evasion machinery operated by a wide range of human malignancies and may thus be considered as a potential target for immunotherapy of cancer. Receptors of VISTA through which this protein transmits immunosuppressive signals under various normal and pathological conditions remain to be identified.</div></div><div><h3>Materials and methods</h3><div>To conduct the study, we used human recombinant proteins and various human cell lines as well as primary T cells. A wide range of techniques including tissue culture and co-cultures, Western blot analysis, on-cell Western, ELISA, co-immunoprecipitation, biochemical assays and synchrotron radiation circular dichroism spectroscopy were employed.</div></div><div><h3>Results</h3><div>Here we report for the first time that VISTA has affinity to programmed cell death protein 1 (PD-1) and binds it as a ligand. We found that when interacting with PD-1, VISTA suppresses interleukin 2 production by T helper cells. These effects were confirmed in the <em>in vitro</em> and <em>ex vivo</em> experiments. Affinity of VISTA to PD-1 was also characterised and found to be moderate, with a <em>K</em><sub>d</sub> of ∼2.3 μM detected by synchrotron radiation circular dichroism spectroscopy.</div></div><div><h3>Conclusions</h3><div>These results open a completely new chapter in our understanding of the concept of immune checkpoint proteins, where some of them clearly show both ligand and receptor activities and display multifunctional properties.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101533"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145748242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives 蛋白质工程克服癌症免疫治疗中关键细胞因子的限制：目前的方法和未来的展望

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-06-21 DOI: 10.1016/j.iotech.2025.101064

U. Salazar , P. Cioffi , B. Taskoparan , I. Moraga , S. Mitra , J. vom Berg

{"title":"Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives","authors":"U. Salazar , P. Cioffi , B. Taskoparan , I. Moraga , S. Mitra , J. vom Berg","doi":"10.1016/j.iotech.2025.101064","DOIUrl":"10.1016/j.iotech.2025.101064","url":null,"abstract":"<div><div>Given their central role in immune regulation, cytokines have long been considered attractive therapeutic agents, particularly in cancer immunotherapy. Despite a strong preclinical and clinical rationale, only a limited number of cytokines have been approved for cancer immunotherapy to date, and their clinical use often remains limited to specialized centers. Here we briefly review the biological traits that make some of the most widely studied cytokines—specifically, interleukin (IL)-2, IL-15, and IL-12—attractive for immunotherapy and, conversely, the challenges encountered during their clinical translation. Focusing on these three cytokines in the context of systemic or local delivery, we highlight protein engineering strategies that address challenges to increase their therapeutic index, such as poor tolerability, short serum half-life, and pleiotropy. For systemic delivery, these strategies include the use of shielded cytokines and immunocytokines to elicit tissue context-dependent activity by taking advantage of unique characteristics of the tumor microenvironment (TME). Half-life extension domains to increase serum prevalence, partial agonism to restrict activity to intended effector cells, and <em>cis</em>-targeting are also discussed. For local administration, we review protein modifications intended to increase prevalence in the tumor, including increased size, adhesion to the extracellular matrix, targeting tumor-associated antigens, or targeting immune effector cells in the TME. Looking ahead, we anticipate the development of novel approaches such as reversible, context-dependent switches, and an increasing number of combinations of individual modifications.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101064"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145128268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

73eP CCL1 and CXCL12 inflammatory cytokines are associated with bladder cancer and clinical parameters 73eP CCL1和CXCL12炎性因子与膀胱癌及临床参数相关

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101155

L. Elsalem , B. Alarareh , N. Al-Azzam , O. Halalsheh

引用次数: 0

97P Lifileucel infusions in the real world: A single-institution series 97P现实世界中的Lifileucel注射：单一机构系列

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101182

S.P. Patel , A. Farmer , C. Davis , C. Davies , T. Van , M. Thames , L. Barcus , N. Kelemen , J. Gutman , L. Mantle , T. Medina

引用次数: 0

56P Plasmacytoid dendritic cells in melanoma-draining lymph nodes are a potential predictive biomarker for immune checkpoint blockade 黑色素瘤引流淋巴结中的浆细胞样树突状细胞是免疫检查点阻断的潜在预测性生物标志物

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101139

E. Reynaud , S. Belherazem , Ö.C. Sener , S. Hofmann , A. Acari , P. Lodha , S. Hemanna , N. Coianiz , V. Ast , S. Tugues , L.C. Dieterich

引用次数: 0

111P MET-CAR cytokine induced killer lymphocytes: A novel immunotherapy for malignant pleural mesothelioma 111P MET-CAR细胞因子诱导杀伤淋巴细胞：恶性胸膜间皮瘤的一种新的免疫疗法

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101196

H.M.W. Munir , A.M. Lombardi , F. Picca , A. Proment , J. Tao , L. Giordanengo , L. Minori , V. Botta , M. Lambertin , F. Bersani , F. Napoli , L. Righi , S. Novello , G. Scagliotti , D. Sangiolo , R. Taulli , E. Vigna

引用次数: 0

113P CTO1681 attenuates CRS-driving cytokines without compromising CAR T cell-mediated tumor killing in vitro 113P CTO1681在体外不影响CAR - T细胞介导的肿瘤杀伤的情况下减弱crs驱动细胞因子

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101198

M. Howell , J. Craigo , M. Frigault , N. Todd , T. Whalen

引用次数: 0

37P Peripheral blood immune cell profiling by single cell RNA sequencing (scRNA-seq) to predict anti-PD1 efficacy in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) 37P外周血免疫细胞谱单细胞RNA测序（scRNA-seq）预测头颈部复发和/或转移性鳞状细胞癌（R/M SCCHN）抗pd1疗效

Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101120

S. Carlier , G. de Streel , S. Lucas , J-P. Machiels

引用次数: 0